An important aspect that needs to be further addressed is whether downregulation of praja2 by the RNAi-nanoparticles potentiates the efficacy of other therapeutic strategies, such as chemotherapy and/or radiotherapy that are currently being used for GBM treatment. This evidence concerns the gene PJA2 and glioblastoma.